Medicine and Dentistry
Predictor
100%
Human Immunodeficiency Virus
83%
Proteinase Inhibitor
83%
Highly Active Antiretroviral Therapy
83%
Patient
66%
RNA
50%
Cell Count
33%
Plasma
33%
T-Helper Cell
33%
Treatment Response
16%
Age
16%
Logistic Regression Analysis
16%
Odds Ratio
16%
Antiretroviral Therapy
16%
Cohort Analysis
16%
Combination Therapy
16%
Population Research
16%
Immune Deficiency
16%
Reverse-Transcriptase Inhibitor
16%
Ritonavir
16%
Adverse Drug Reaction
16%
Indinavir
16%
Nelfinavir
16%
Person
16%
Adjustment
16%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
83%
Proteinase Inhibitor
83%
RNA
50%
Controlled Clinical Trial
50%
Clinical Trial
50%
RNA Directed DNA Polymerase Inhibitor
16%
Immune Deficiency
16%
Ritonavir
16%
Adverse Drug Reaction
16%
Indinavir
16%
Nelfinavir
16%
Neuroscience
HIV
83%
Protease Inhibitor
83%
RNA
50%
Reverse Transcriptase Inhibitors
16%
Ritonavir
16%
Nelfinavir
16%
Suppression
16%
Indinavir
16%
Immunology and Microbiology
Human Immunodeficiency Virus
83%
Viral Load
33%
CD4 Lymphocyte Count
33%
Blood Plasma
33%
Immunodeficiency
16%
Age
16%
Population Research
16%
Drug Hypersensitivity
16%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus
83%
Virus Load
33%
CD4 Lymphocyte Count
33%
Population Research
16%
Age
16%
Ritonavir
16%
Nelfinavir
16%
Adjustment
16%
Cohort Study
16%